Sangamo Therapeutics, Inc. (SGMO) saw its loss narrow to $9.62 million, or $0.14 a share for the quarter ended Dec. 31, 2016. In the previous year period, the company reported a loss of $14.01 million, or $0.20 a share.
Revenue during the quarter went down marginally by 2.18 percent to $8.92 million from $9.12 million in the previous year period.
Operating loss for the quarter was $9.83 million, compared with an operating loss of $15.67 million in the previous year period.
"Early this year we rebranded our company as Sangamo Therapeutics, underscoring our focus on clinical development of genomic therapies using our industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy," said Sandy Macrae, chief executive officer of Sangamo. "With our recently expanded capabilities in clinical development, manufacturing and commercial planning, Sangamo Therapeutics is now a company where science is a means to develop new medicines with the potential to transform the lives of patients living with serious genetic diseases."
For financial year 2017, Sangamo Biosciences projects revenue to be in the range of $14 million to $19 million.
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: editor@irisindia.net
